Published in Leukemia on April 01, 2008
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid (2010) 0.89
Multiple myeloma. Clin Cases Miner Bone Metab (2012) 0.81
How best to use new therapies in multiple myeloma. Blood Rev (2010) 0.81
The research mission in myeloma. Leukemia (2008) 0.75
Diazoxide-mediated growth inhibition in human lung cancer cells via downregulation of beta-catenin-mediated cyclin D1 transcription. Lung (2008) 0.75
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol (2017) 0.75
Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood (1998) 3.69
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet (1997) 3.11
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A (2000) 2.81
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood (2001) 2.48
Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood (1998) 2.36
Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 2.29
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood (1996) 2.21
Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol (2007) 2.14
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia (2011) 2.12
WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res (2001) 2.12
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia (2009) 1.97
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia (2006) 1.71
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia (2006) 1.39
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia (2008) 1.24
Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood (2000) 1.21
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia (2013) 1.21
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia (2007) 1.18
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood (2001) 1.17
Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell (1999) 1.16
Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia (2002) 1.15
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood (2001) 1.15
Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood (2000) 1.09
Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia (2010) 0.97
Selective expression of one c-myc allele in two human myeloma cell lines. Cancer Res (1996) 0.95
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia (2007) 0.92
CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood (1997) 0.91
Expression and mutation status of candidate kinases in multiple myeloma. Leukemia (2007) 0.87
Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. Ann Oncol (2000) 0.87
Dysregulation of c-myc in multiple myeloma. Curr Top Microbiol Immunol (1997) 0.85
Multiple myeloma. Hematology Am Soc Hematol Educ Program (2001) 0.84
Maintained rules of development in a mouse B-cell tumor. Leukemia (2005) 0.84
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death Dis (2013) 0.83
Ploidy status rarely changes in myeloma patients at disease progression. Leuk Res (2005) 0.81
Coordinate silencing of myeloma-specific genes in myeloma x T lymphoma hybrids. J Immunol (1993) 0.81
Initiation and maintenance of multiple myeloma. Semin Hematol (1999) 0.77
Identification of consensus genes expressed in plasmacytomas but not B lymphomas. Curr Top Microbiol Immunol (1990) 0.75